Review of drug development and therapeutic role of cholinesterase inhibitors in Alzheimer's disease
- 1 July 2002
- journal article
- review article
- Published by Wiley in Drug Development Research
- Vol. 56 (3) , 347-353
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s diseaseNeurology, 2001
- Open-Label, Multicenter, Phase 3 Extension Study of the Safety and Efficacy of Donepezil in Patients With Alzheimer DiseaseArchives of Neurology, 2001
- Cholinesterase Inhibitors for Alzheimer??s DiseaseDrugs, 2001
- Galantamine in ADNeurology, 2000
- Preferential Cerebrospinal Fluid Acetylcholinesterase Inhibition by Rivastigmine in HumansJournal of Clinical Psychopharmacology, 1999
- Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial Commentary: Another piece of the Alzheimer's jigsawBMJ, 1999
- Guidelines for Conducting Bridging Studies in Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 1998
- Donepezil Improves Cognition and Global Function in Alzheimer DiseaseA 15-Week, Double-blind, Placebo-Controlled StudyArchives of internal medicine (1960), 1998
- Economic Considerations in Alzheimer's DiseasePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1998
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's diseaseNeurology, 1998